Evidence in T1D is limited to small, short-term, randomized clinical trials (RCTs) and a few observational studies focusing on surrogate outcomes such as glycemic control and weight loss 8,9,10,11,12
Over time, glp-1 helps regulate both appetite and glucose metabolism, allowing patients to decrease their calorie consumption and lose weight without feeling hungry
There is still work to be done on the primary care side with telemedicine
Patients with type 2 diabetes and established atherosclerotic cardiovascular disease represent a particularly appropriate population for semaglutide therapy
Gabrilovich, D.I., Velders, M.P., Sotomayor, E.M
But what we are pretty much sure of now, which has been clarified over the past two decades or so, is there's a very very strong biological basis for developing obesity